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Abstract
Background: Fatigue is a common and debilitating symptom for patients with incurable cancer receiving systemic
treatment with palliative intent. There is evidence that non-pharmacological interventions such as graded exercise
therapy (GET) or cognitive behaviour therapy (CBT) reduce cancer-related fatigue in disease-free cancer patients and
in patients receiving treatment with curative intent. These interventions may also result in a reduction of fatigue in
patients receiving treatment with palliative intent, by improving physical fitness (GET) or changing fatigue-related
cognitions and behaviour (CBT). The primary aim of our study is to assess the efficacy of GET or CBT compared to
usual care (UC) in reducing fatigue in patients with incurable cancer.
Methods: The TIRED study is a multicentre three-armed randomised controlled trial (RCT) for incurable cancer patients
receiving systemic treatment with palliative intent. Participants will be randomised to GET, CBT, or UC. In addition to UC,
the GET group will participate in a 12-week supervised exercise programme. The CBT group will receive a 12-week CBT
intervention in addition to UC. Primary and secondary outcome measures will be assessed at baseline, post-intervention
(14 weeks), and at follow-up assessments (18 and 26 weeks post-randomisation). The primary outcome measure is fatigue
severity (Checklist Individual Strength subscale fatigue severity). Secondary outcome measures are fatigue
(EORTC-QLQ-C30 subscale fatigue), functional impairments (Sickness Impact Profile total score, EORTC-QLQ-C30
subscale emotional functioning, subscale physical functioning) and quality of life (EORTC-QLQ-C30 subscale QoL).
Outcomes at 14 weeks (primary endpoint) of either treatment arm will be compared to those of UC participants. In
addition, outcomes at 18 and 26 weeks (follow-up assessments) of either treatment arm will be compared to those of
UC participants.
Discussion: To our knowledge, the TIRED study is the first RCT investigating the efficacy of GET and CBT on reducing
fatigue during treatment with palliative intent in incurable cancer patients. The results of this study will provide
information about the possibility and efficacy of GET and CBT for severely fatigued incurable cancer patients.
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Background
Cancer is a leading cause of mortality worldwide, with 8.2
million deaths in 2013 [1]. As a result of improvements in
treatment options for certain cancers, substantial progress
has been made in curative treatment of cancer. Despite
these positive developments, a substantial subgroup of
cancer patients will (eventually) be diagnosed with incur-
able cancer. The medical treatment of incurable cancer
has a palliative intention, with prolonging life as one of its
main aims [2]. For some cancer types, advances in cancer
treatment with palliative intent have resulted in an ex-
tended period of life, resulting in more long-term or
chronic cancer treatment. Next to prolonging life, treat-
ment of incurable cancer should also be aimed at main-
taining quality of life for as long as possible and relieving
physical and psychological symptoms [2]. As a result of
the longer-term treatment of incurable cancer patients, as-
pects regarding quality of life and symptom management
become even more important.
Fatigue in patients with incurable cancer
Fatigue is one of the most commonly reported symptoms
during systemic treatment for incurable cancer, being re-
ported by up to 99% of patients [3–7]. There are various
ways to define fatigue, but cancer-related fatigue (CRF) is
a term that is most widely used to address this symptom.
The National Comprehensive Cancer Network (NCCN)
defines CRF as “a distressing, persistent, subjective sense of
physical, emotional and/or cognitive tiredness or exhaus-
tion related to cancer or cancer treatment that is not pro-
portional to recent activity and interferes with usual
functioning” [8]. Studies show that CRF is among the most
distressing symptoms [3, 9, 10] and is associated with re-
duced quality of life, poor performance status, and diffi-
culty performing daily activities [3, 4, 11]. Many factors
are likely to contribute to CRF in patients with incurable
cancer. The multiple causes of CRF can result from the
underlying disease, from secondary factors such as an-
aemia, infection, dehydration, and treatment side effects,
or from loss of muscle mass. Apart from these physical
factors, depression and anxiety can also contribute to
CRF. There is also evidence suggesting that cognitive and
behavioural factors, such as sleeping problems, fatigue
catastrophising, and inappropriate coping are related to
fatigue in patients with incurable cancer [12].
Management of CRF in incurable cancer patients should
first focus on identifying and treating somatic causes, for
example anaemia or hypothyroidism [8]. Yet, often no
somatic cause for CRF can be found. When no somatic
cause can be identified, the management of CRF can in-
volve pharmacological treatment or non-pharmacological
interventions. Thus far, no recommendation for a specific
drug treatment for fatigue in palliative care patients could
be given [13]. There is also no evidence-based non-
pharmacological intervention for CRF in incurable cancer
patients. Two non-pharmacological approaches, Graded
Exercise Therapy (GET) and Cognitive Behaviour Therapy
(CBT), seem promising interventions based on findings
from studies addressing CRF in other cancer patients that
will be discussed below.
Exercise interventions for CRF in cancer patients
In contrast to the old advice to ‘get plenty of rest’ during
cancer treatment, patients are now encouraged to opti-
mise levels of physical activity [8]. A low level of physical
activity during cancer treatment can lead to decreased
physical functioning by a substantial loss of cardiopulmo-
nary fitness and muscle mass [14]. On the other hand, in-
creasing physical activity has been suggested as helpful in
reducing CRF by improving physical capacity, resulting in
a reduced effort to perform everyday activities [8]. Cramp
& Byron-Daniel (2012) suggested that exercise interven-
tions can help to reduce CRF both during and after adju-
vant treatment for cancer [15]. Efficacy of exercise
interventions for the subgroup of patients receiving cancer
treatment with palliative intent was not examined in this
Cochrane systematic review. Nonetheless, a systematic re-
view by Lowe et al. (2009) did provide evidence that exer-
cise interventions are feasible in patients with incurable
cancer as the majority of participants were able to tolerate
various physical activity interventions [16]. Three of the
six reviewed studies had fatigue as one of the outcome
measures and all three reported a reduction in fatigue
[17–19]. However, the methodological quality of these
pilot studies was evaluated as poor and only one study
had a control condition [16].
Following the NCCN recommendations for exercise
programs, our research group developed a 6-week GET
intervention that was tailored to the physical fitness level
of each participant and began at a low level of intensity
and duration, progressed slowly, and was modified when
the participant’s condition changed. This intervention
was tested for feasibility and efficacy was explored in an
uncontrolled pilot study of 26 incurable cancer patients.
GET was not only feasible in terms of participants’ ad-
herence and evaluation, but also efficacious with signifi-
cant improvements in self-reported fatigue and quality
of life [20]. A large-scale randomised controlled trial
(RCT) is needed to confirm these promising results.
Cognitive behaviour therapy for CRF in cancer patients
Most research on the efficacy of CBT for CRF has been
done in cancer survivors or cancer patients receiving can-
cer treatment with curative intent. Systematic reviews and
meta-analyses have indicated that CBT can reduce fatigue
in cancer survivors [21, 22]. Two RCTs performed by our
research group have demonstrated that fatigue and func-
tional impairments in severely fatigued cancer survivors
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can be significantly reduced by CBT for CRF [23, 24]. This
fatigue-specific intervention targets several cognitive-
behavioural perpetuating factors of CRF. The intervention
is based on the underlying assumption that cancer treat-
ment and/or the cancer itself may trigger fatigue (precipi-
tating factors), but that other factors such as sleep
disturbance, physical inactivity, and dysfunctional thoughts
about fatigue might be responsible for the persistence of
fatigue (perpetuating factors) [25]. Positive intervention ef-
fects of CBT for CRF were sustained at 2-years follow-up
[26]. The efficacy of CBT for CRF compared to usual care
was also assessed in an RCT aimed at cancer patients dur-
ing cancer treatment with curative intent [27]. Despite a
significant reduction in fatigue immediately after the inter-
vention for patients in the CBT arm, no differences were
observed between these two conditions at follow-up with
effects diminishing after seven months [28]. It should be
noted though, that being severely fatigued was not an entry
criterion for this RCT, and thus a floor effect may be
present in this trial.
While there are no RCTs to date that investigated the
efficacy of CBT specifically aimed at reducing fatigue in
incurable cancer patients receiving cancer treatment
with palliative intent, two previous RCTs provide indir-
ect support for the positive effects of CBT on fatigue
outcomes in a sample of cancer patients of whom a sub-
group had incurable cancer [29, 30]. Although these
RCTs did show an overall effect on fatigue, it is not clear
whether this can be generalised to the group of cancer
patients receiving treatment with palliative intent since
subgroup analyses were not performed. Based on our
previous experience with CBT for CRF in both cancer
survivors and patients receiving cancer treatment with
curative intent, and results of a recent study which sug-
gested that the same perpetuating psychosocial factors
are associated with fatigue in patients receiving cancer
treatment with palliative intent [12], we think it is im-
portant to examine the efficacy of CBT for CRF in an
RCT for this new target population.
The role of physical activity and fitness versus fatigue-
related cognitions as mediators of the reduction in CRF
Exercise interventions aiming to reduce CRF in cancer pa-
tients are based on the assumption that a lack of physical
activity and deconditioning during cancer treatment can
worsen fatigue [31]. It is assumed that with exercise inter-
ventions physical activity and fitness can be increased,
resulting in a reduction in CRF. CBT aimed at reducing
CRF in cancer patients is based on the assumption that
several fatigue-related cognitions (i.e., low self-efficacy and
catastrophising thoughts) and behaviours are related to
the persistence of fatigue [25]. Targeting cognitions with
CBT is assumed to result in less dysfunctional thoughts
about fatigue, which contributes to the reduction in CRF.
Although these assumptions are widespread, the role of
an increase in physical activity and fitness versus a change
in fatigue-related cognitions in reducing CRF has not yet
been investigated in interventions for patients with incur-
able cancer. To investigate which factors contribute to a
reduction in CRF, mediation analysis can be helpful. This
technique provides insight into which factors mediate the
expected reduction in CRF brought on by GET on CRF.
Mediation analysis can thereby help us to better under-
stand how interventions work [32].
Aims of the TIRED study
We designed a multicentre RCT to test the efficacy of
either GET or CBT compared to Usual Care (UC) in re-
ducing fatigue (primary outcome) in incurable cancer
patients receiving systemic treatment with palliative in-
tent. In addition, the efficacy on improving quality of life
and functional impairment will be studied. All outcomes
will be assessed at baseline, and at 14, 18 and 26-weeks
post-randomisation. We will assess the efficacy of GET
or CBT compared to UC directly post-intervention at
14-weeks post-randomisation, which is the primary end-
point of this study. In addition, we will determine
whether the expected intervention effects are sustained
at follow-up assessments (18-weeks and 26-weeks post-
randomisation). Furthermore, if GET and/or CBT are ef-
ficacious in reducing CRF, we will perform a mediation
analysis to test if the changes in four variables (i.e., phys-
ical activity, physical fitness, self-efficacy with respect to
fatigue, and/or fatigue catastrophising) mediate the re-
duction in fatigue.
Methods
Design
A non-blinded multicentre RCT (the TIRED study) will
be conducted to evaluate the efficacy of GET and CBT
compared to UC for severely fatigued incurable cancer
patients receiving cancer treatment with palliative intent.
Participants
Inclusion and exclusion criteria are listed in Table 1. Pa-
tients diagnosed with incurable cancer, receiving systemic
treatment with palliative intent, and with a cancer treat-
ment plan based on an expected survival of at least
6 months as judged by their oncologist, will be further
assessed for eligibility by nurses and oncologists. We will
include patients diagnosed with one of the following can-
cer types: breast, colorectal, prostate, renal cell, bladder,
endometrial, ovarian, cervical, bone and soft tissue, or
melanoma. Systemic cancer treatment may include
chemotherapy, hormone therapy, targeted therapy, and/or
immunotherapy, possibly combined with surgery and/or
radiotherapy. The presence of severe fatigue reflected by a
score of 35 or higher on the subscale fatigue severity of
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the Checklist Individual Strength (CIS-fatigue) will be
used as a criterion for study entry [33].
Recruitment
Nurses and oncologists working at oncology outpatient
clinics of two University-affiliated hospitals and seven Re-
gional hospitals in the Netherlands will recruit patients.
Patients will be screened for the presence of severe fatigue
as part of clinical care by administering the CIS-fatigue
prior to the start or during systemic treatment with pallia-
tive intent when patients visit the outpatient clinic. When
eligible patients are severely fatigued, the nurse or oncolo-
gist will present the TIRED study by giving patients written
information and solicit permission to have a researcher
contact them. Those patients who agree to be contacted
will be called by the coordinating researcher (HP), who
will further inform them about the details and purpose of
the study and invite them to participate. A follow-up
phone call will be scheduled one week after the first phone
call to address questions and determine if patients are will-
ing to participate.
Procedure
Eligible patients willing to participate in the study will
be asked to sign informed consent upon which they will
be invited by a research assistant to complete the base-
line assessment (T0) at their own hospital. Upon
completion of T0, the research assistant will use a central
web-based randomisation service to randomly allocate a
participant to one of the three study arms: (1) GET in
addition to UC; (2) CBT in addition to UC; or (3) control
group receiving UC (see Fig. 1). Participants assigned to
GET or CBT will start the intervention approximately two
weeks after T0. Both interventions will be delivered at or
near their own hospital over a period of 12 weeks. Partici-
pants assigned to CBT will complete a set of additional
questionnaires to determine relevant intervention modules
prior to the first intervention session. Participants assigned
to GET will complete an additional submaximal test to de-
termine physical fitness during the first intervention ses-
sion. At 14 weeks, participants are invited by the research
assistant to complete the post-intervention assessment
(T1) at the hospital. Follow-up assessments at 18 weeks
(T2) and 26 weeks (T3) are entirely web-based and will be
completed at home. For participants that do not have
Internet access, a paper version of the follow-up question-
naires will be send to their home address, which can be
returned in a self-addressed, pre-stamped envelope.
Randomisation
A central web-based randomisation service provided by an
independent statistician will be used. Randomisation will
be stratified by centre. We will use block randomisation to
reach the same number of participants in all study arms.
The ordering of blocks and their respective size will be un-
known for the research assistants and coordinating re-
searcher. When possible, minimisation on gender will be
performed in order to balance the gender distribution in
all study arms. If block randomisation restricts the choice
to two or only one study arm, minimisation will always be
overruled by block randomisation. A research assistant will
perform allocation upon completion of T0 in the presence
of the participant.
Interventions
Graded exercise therapy
Participants assigned to the GET group will receive a 12-
week supervised exercise programme in addition to UC.
The treatment protocol ‘GET for fatigue in incurable
cancer patients’ was developed by the study investigators
in cooperation with a physiologist (MH) and physical
therapist (MN) experienced in exercise programmes for
cancer patients. The treatment protocol was based on
the protocol for a previous pilot-study in patients with
incurable cancer [20]. Physical therapists affiliated with
the participating hospitals or from local physical therapy
centres will deliver the GET. All therapists will be
instructed about the treatment protocol and use of regis-
tration forms before enrolment of participants. Through-
out the study, supervision will be provided upon request
by a physical therapist (MN).
Table 1 Inclusion and exclusion criteria
Inclusion criteria
(1) Age≥ 18 years.
(2) Able to read, speak and write the Dutch language.
(3) Diagnosis of incurable cancer (i.e. breast, colorectal, prostate, renal
cell, bladder, endometrial, ovarian, cervical, bone and soft tissue
cancer, or melanoma).
(4) Scheduled for or receiving systemic cancer treatment with palliative
intent (i.e., chemotherapy, and/or hormone therapy, and/or targeted
therapy, and/or immunotherapy, possibly combined with surgery
and/or radiotherapy).
(5) Cancer treatment plan based on an expected survival of≥
6 months as judged by their oncologist.
(6) Severely fatigued (CIS-fatigue score≥ 35).
Exclusion criteria
(1) Treatable somatic cause that could explain the presence of severe
fatigue (other than the underlying disease and the cancer
treatment itself).
(2) Karnofsky Performance Status < 70.
(3) Symptomatic brain metastases.
(4) Severe cognitive problems.
(5) Not able to walk at least 6 min successively.
(6) Contra-indication for physical exercise.
(7) Current treatment by a psychiatrist or psychologist for a psychiatric
disorder.
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GET will be given by physical therapists individually
or in small groups with a maximum of 5 participants,
depending on the accrual rate. During the intake session,
the physical therapist will collect information about a
participant’s physical fitness level (by means of a sub-
maximal test) and physical limitations. Participants will
formulate treatment goals in activities of daily living to-
gether with the physical therapist, such as performing
activities or leisure interests in the foreseeable future
that are currently difficult to perform because of a lack
of muscle strength or cardiopulmonary fitness. After the
intake session, participants will receive weekly two-hour
sessions of individually graded training supported by a
physical therapist and adjusted to their abilities. In order
to adjust the training to an individual participant, their
heart rate reserve (HRR) and muscle strength (by means
of one-repetition maximum [1RM] tests) will be deter-
mined during first session and after every three sessions.
The two-hour GET sessions will include a warming up
(10 min), high intensity aerobic interval training
(35 min), a break (15 min), resistance training (35 min),
and a cooling down (10 min). Additionally, there are
15 min available for evaluation of the GET session. In
addition to this supervised session, participants are of-
fered to practise in a second weekly session. After every
three sessions, training progress will be evaluated and
the programme will be adjusted by means of the newly
determined HRR and 1RM and discussion of formulated
treatment goals.
Aerobic training The aerobic training will consist of
cycling on an interval basis prior to the resistance train-
ing. Intervals will include alternated bicycling for four
minutes at 60% (increasing to 80%) of participants’ HRR
with three minutes on 35% (increasing to 50%) of HRR.
Heart rate will be monitored during the aerobic training
using a Polar® breast band (Polar T31 Breast Band, 2008,
Polar Electro, Finland). We will use the Borg Scale of
Perceived Exertion after each cycling interval to gauge
the perceived intensity of the aerobic training [34].
Fig. 1 Flowchart of the TIRED study
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Resistance training The resistance program will include
a circuit of seven exercises targeting large muscle groups
important for activities of daily living. The following ex-
ercises will be executed: (1) leg press; (2) lunge; (3) verti-
cal row; (4) lateral pull down; (5) abdominal crunch; (6)
pull over; and (7) bench press. Exercises will be executed
at 60-80% of participants’ 1RM and will consist of 3 sets
of 8 to 12 repetitions. Some exercises will be performed
more often based on the participants’ difficulties in this
area and his or her goals in activities of daily living. Pro-
gression will be conducted by the graded activity
principle, which states that the focus is on successes and
positive experiences and that negative experiences will
be prevented as much as possible [35].
Cognitive behaviour therapy
Participants in the CBT group will receive ‘CBT for fatigue
in incurable cancer patients’ in addition to UC. This inter-
vention was developed by the study investigators based on
the evidence-based protocol of CBT for post-cancer fa-
tigue [23, 26]. Adaptations were done for application with
our new target population. This adapted CBT will consist
of a maximum of ten sessions over a period of 12 weeks
(i.e., one assessment session and maximum nine individual
one-hour face-to-face treatment sessions). Qualified and
trained psychologists will deliver CBT for fatigue. Prior to
intervention delivery, all therapists will receive a three-day
training provided by two experienced clinical psycholo-
gists (HK and TB). This training will provide background
and rationale for each of the intervention modules and in-
volves role-playing to practise the intervention compo-
nents. An experienced clinical psychologist (HK) will
provide on-going supervision to CBT therapists through-
out the study.
CBT for fatigue in incurable cancer patients includes
several modules aimed at fatigue-perpetuating cognitions
and behaviours. Participants randomised to CBT will
complete a set of additional questionnaires prior to the
first intervention session to assess potential perpetuating
factors (see Table 2). During the first intervention ses-
sion it will be determined by the therapist which factors
are applicable for the particular patient, which leads to a
tailored-made intervention as only the relevant treat-
ment modules will be selected. The goal of CBT is re-
duction of severe fatigue and fatigue-related disability.
All participants will start with setting their treatment
goals. Participants will be helped to formulate concrete
goals in behavioural terms, such as resuming activities
or leisure interests in the foreseeable future that are dis-
continued because of being severely fatigued. Then,
therapists and participants will work on adjusting the
fatigue-perpetuating factors that are applicable to the in-
dividual participant: (1) sleep problems and deregulated
sleep-wake cycle; (2) dysfunctional cognitions regarding
cancer (prognosis) and cancer treatment; (3) dysfunc-
tional fatigue-related cognitions; (4) deregulated activity
pattern; (5) negative social interactions and low per-
ceived social support. Each of these perpetuating factors
corresponds to a treatment module:
Module 1: Regulation of sleep-wake cycle and im-
proving sleep hygiene The patient will be explained
how the ‘biological clock’ can be reset, in order to estab-
lish a consistent sleep-wake pattern with regular bed and
wake-up times and no day-time napping. If necessary,
advice with respect to sleep hygiene will be given.
Module 2: Reformulate dysfunctional cognitions re-
garding cancer and cancer treatment This module
aims to help the patient formulate more helpful beliefs
to improve his or her coping with the fact of having in-
curable cancer, including fear of the future, and experi-
encing side effects of cancer treatment. Dysfunctional
beliefs will be discussed and restructured.
Module 3: Reformulate dysfunctional cognitions re-
garding fatigue The goal is to increase self-efficacy with
respect to fatigue, reduce fatigue catastrophising, and
help the patient to focus less on fatigue.
Module 4: Regulation of activity Two activity patterns
will be distinguished on the basis of actigraphy (see
‘Outcomes’): relatively active or low active. Some se-
verely fatigued patients have a persistent low level of
physical activity, while others have a more fluctuating
activity pattern with bursts of activities followed by
periods of inactivity (‘all-or-nothing behaviour’). Both
activity patterns can perpetuate fatigue. Relatively ac-
tive participants are helped to spread their physical,
mental, and social activities more evenly over the day
and week. Subsequently, participants will gradually in-
crease their physical activity level by means of a daily
walking or cycling program of their choice. The
chosen activity will be gradually and systematically in-
creased. Low active participants will be motivated to
immediately start with the graded activity program.
By increasing physical activity, participants’ self-
efficacy with respect to physical activity and fatigue
will often change positively. Eventually, participants
will also increase mental and social activities.
Module 5: Improve social support and change un-
helpful social expectations This module is directed at
modifying the patients’ unhelpful cognitions regarding
their social environment, as they can maintain fatigue.
Unrealistic expectations towards others are detected and
disputed. Patients will practise with exercises in order to
change these unhelpful cognitions and are encouraged
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to involve their partner in this module. Also, coping
strategies in contact with others, such as family, friends,
and/or colleagues, will be discussed.
After addressing the perpetuating factors of fatigue,
patients will gradually work towards realising the treat-
ment goals formulated at the start of the intervention.
At the end of the intervention it is discussed how to deal
with new episodes of fatigue, that may be induced when
starting further lines of systemic cancer treatment.
Usual care and use of co-intervention
All participants will be treated for incurable cancer in
concordance with national and regional cancer clinical
practice guidelines of the Dutch Comprehensive Cancer
Centres [36]. Participants assigned to the control group
have no access to one of the two study interventions,
but may be referred by their oncologist or general prac-
titioner to physical therapists or psychologists as part of
UC. Participants assigned to CBT will be asked not to
follow an exercise programme as part of UC simultan-
eously, and participants assigned to GET will be asked
not to follow a psychological intervention as part of UC
simultaneously. We will collect information on whether
participants have engaged in exercise programmes or
psychological interventions as part of UC at all three
post-randomisation assessments (T1, T2, and T3).
Table 2 Instruments to assess which CBT modules are indicated
CBT Module Instrument Rating (RANGE) Cut-off value
Sleep problems and deregulated
sleep-wake cycle
Sleep-wake diary Bedtimes and wake up times of 12 consecutive
days and nights
Visual inspection of
bedtimes and wake up
times
Sickness Impact Profile [41]:
subscale Sleep and Rest
Number and type of items endorsed, weighted
according to a standardised weighting scheme
Score≥ 60
Symptom Checklist-90 [52]:
subscale Sleeping Problems
5-point Likert scale (3–15) Score≥ 6
Dysfunctional cognitions regarding
cancer (prognosis) and cancer
treatment
Impact of Event Scale [53]:
subscale Intrusion
subscale Avoidance
4-point Likert scale (7–28)
4-point Likert scale (8–32)
Score≥ 10
Score≥ 10
Pictorial Representation of
Illness and Self Measure [54]
Self-illness separation (SIS) in cm
Self-fatigue separation (SFS) in cm
Fatigue-related suffering:
SIS > SFS
Illness-related suffering:
SFS > SIS
Illness Cognition Questionnaire
[55, 56]:
subscale Acceptance
subscale Helplessness
4-point Likert scale (6–24)
4-point Likert scale (6–24)
Score≤ 12
Score > 14
Beck Depression Inventory-II Pri-
mary Care [57]
4-point Likert scale (0–21) Score≥ 4
Hospital Anxiety and Depression
Scale [58]:
subscale Anxiety
subscale Depression
4-point Likert scale (0–21)
4-point Likert scale (0–21)
Score≥ 9
Score≥ 9
Dysfunctional fatigue-related
cognitions
Fatigue Catastrophising Scale
[45]
5-point Likert scale (10–50) Score≥ 16
Self-Efficacy Scale [26, 59] 4-point Likert scale (7–28) Score≤ 19
Illness Management
Questionnaire-factor III [60]
6-point Likert scale (9–54) Score≥ 30
Anxiety for Fatigue 4-point Likert scale (8–32) Score≥ 14
Deregulated activity pattern Actigraphy during 12
consecutive days
Number of days with a mean physical activity
level > 66
Low-active: 0-1
Relatively-active: ≥ 2
Sickness Impact Profile [41]:
subscale Social Interactions
Number and type of items endorsed, weighted
according to a standardised weighting scheme
Score≥ 100
Checklist Individual Strength
[33]: subscale Concentration
7-point Likert scale (5–35) Score≥ 18
Negative social interactions and low
perceived social support
Van Sonderen Social Support
Inventory [61] (shortened
version):
subscale Negative Interactions
subscale Discrepancies
4-point Likert scale (7–28)
4-point Likert scale (8–32)
Score≥ 10
Score≥ 14
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Adverse events
All adverse events (AEs) and serious adverse events
(SAEs) reported spontaneously by the participants or ob-
served by the GET or CBT therapists will be recorded. All
reported AEs will be followed until they have aborted, or
until a stable situation has been reached. SAEs are defined
as any medical occurrence that results in death, is life
threatening, requires hospitalisation, results in persistent
or significant disability or incapacity, or a new event of the
study likely to affect the safety of participants. SAEs will
be reported to the Research Ethics Committee of the
University-affiliated hospital that approved the study
protocol. At post-intervention assessment (T1), patients
will be asked whether they think they currently experience
or have experienced AEs as a result of the intervention
(GET or CBT) they have received. In case of an affirmative
answer, patients will be asked to specify these AEs.
Adherence and treatment integrity
Data will be collected with respect to participants’ attend-
ance of GET or CBT sessions, dropout from the interven-
tion (<2 sessions attended), and therapists’ adherence to
the protocol. Adherence to GET and CBT intervention
protocols will be determined by means of evaluating the
registration forms completed by therapists, including
components of the intervention protocol that have been
addressed during each session. In addition, with permis-
sion of participants, all CBT sessions will be audio taped
and upon study completion a random sample of 5% will
be analysed to determine treatment integrity.
Refusal of study participation and study dropout
The researcher will record the reasons why patients do
not participate, why participants dropout from the inter-
vention, and why study assessments are not completed
(T1, T2, or T3). Upon completion of the study, these
reasons will be categorised, scored and analysed to gain
insight into the generalisability of the findings.
Outcomes
Outcome measures and data collection time points are
listed in Table 3. The primary endpoint of this study is
the post-intervention assessment (T1), 14 weeks after
randomisation. Primary and secondary outcomes will be
measured at baseline (T0), post-intervention (T1) and
follow-up (T2, T3). Proposed mediators will only be
assessed at T0 and T1.
Primary outcome
Fatigue severity will be measured using the subscale fa-
tigue severity (8 items, 7-point Likert scale) of the
Checklist Individual Strength (CIS-fatigue) [33]. Scores
range from 8–56. A score of 35 points or higher is an in-
dication for severe fatigue. The CIS-fatigue has been
used in previous intervention studies aimed at CRF and
proved to be sensitive to change [23, 27]. The CIS-
fatigue has good reliability (Cronbach’s alpha = 0.88) and
discriminative validity [37].
Secondary outcomes
Fatigue will also be assessed with the symptom scale fa-
tigue (3 items, 4-point Likert scale) of the European Or-
ganisation for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ-C30, ver-
sion 3.0). The EORTC QLQ-C30 is developed for use in
clinical trials in cancer patients [38]. This instrument
consists of five functional and three symptom scales in
addition to a scale on global health related quality of life
(HRQoL), and a number of single items assessing add-
itional symptoms [38, 39]. Total scores on each subscale
are linearly converted to a 0 to 100 scale. Higher scores
represent more fatigue.
The subscale global health status/QoL (2 items, 7-point
Likert Scale) of the EORTC QLQ-C30 will be used to
measure quality of life. A high score indicates good
HRQoL. The EORTC QLQ-C30 is one of the most com-
monly used HRQoL instruments [40] and is known to be
Table 3 Data collection time point of all outcome measures
and proposed mediators
Concept Questionnaire Measurement
time points
T0 T1 T2 T3
Socio-demographics Self-report questionnaire X
Medical
characteristics
Medical chart review X X
Primary outcome:
Fatigue severity CIS fatigue severity X X X X
Secondary outcomes:
Fatigue EORTC QLQ-C30 fatigue X X X X
Quality of life EORTC QLQ-C30 global
health status
X X X X
Functional
impairments
SIP X X X X
EORTC QLQ-C30
emotional functioning
X X X X
EORTC QLQ-C30
physical functioning
X X X X
Proposed mediators:
Physical activity Actigraphy during
12 consecutive days
X X
Physical fitness 6MWT X X
Self-efficacy SES X X
Fatigue
catastrophising
FCS X X
T0 baseline (pre-intervention), T1 post-intervention/UC (14 weeks post-
randomisation), T2 first follow-up assessment (18-weeks post-randomisation),
T3 s follow-up assessment (26-weeks post-randomisation)
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a reliable and valid measure of the quality of life of cancer
patients [38].
Functional impairments will be assessed with two instru-
ments. We will include seven subscales of the Sickness
Impact Profile (SIP) to assess the level of functional impair-
ments [41]. This questionnaire measures the influence of
complaints in different areas of daily functioning. The fol-
lowing subscales will be used: alertness behaviour, sleep,
homemaking, leisure activities, mobility, social interactions,
and ambulation. High scores reflect high levels of func-
tional impairments. The SIP is known to be a reliable in-
strument with sufficient content validity [42]. In addition to
the SIP, functional impairments will also be assessed by the
subscales emotional functioning (4 items, 4-point Likert
scale) and physical functioning (5 items, 4-point Likert
scale, range 0 to 100) of the EORTC QLQ-C30. Raw scores
for both subscales are convertible to a score of 0 to 100. A
high score represents a high level of functioning.
Proposed mediators
Change scores (T1-T0) for each proposed mediator will
be calculated and used for multiple mediation analysis.
The following proposed mediators will be assessed at T0
and T1:
Physical activity The level of physical activity will be
assessed with actigraphy. Participants will be wearing an
actometer around the ankle for twelve consecutive days
and nights following T0 and T1. This actometer is a
motion-sensing device based on a piezo-electric sensor
recording the number of movement at five-minute inter-
vals and with highly reproducible readings [43]. The
mean daily physical activity score over twelve days can
be calculated as a measure of physical activity.
Physical fitness We will assess the level of physical fit-
ness with the Six-Minute Walk Test (6-MWT). This is
an easy to perform and practical submaximal exercise
test that has been increasingly used across various pa-
tient populations. The 6-MWT will be conducted in an
indoor corridor on a pre-measured test-course of 20 me-
ters. Participants will be instructed to walk from one
end to the other while attempting to cover as much dis-
tance as possible during the allotted time. Patients who
normally use walking aids will be allowed to use them
during the test. The total walking distance covered in six
minutes provides an indirect measure of aerobic func-
tional fitness [44].
Self-efficacy with respect to fatigue The seven-item
self-efficacy scale (SES) will be used to measure the
amount of experienced control over fatigue [26]. All
items are scored on a 4-point Likert scale. Higher scores
are indicative for more sense of control.
Fatigue catastrophising We will use the ten-item Fa-
tigue Catastrophizing Scale to measure catastrophising in
response to fatigue [45]. All items are scored on a 5-point
Likert scale. Higher total scores indicate more fatigue
catastrophising.
Sample size calculation
Based on the primary outcome measure of the TIRED
study, efficacy of one or both interventions is demon-
strated when mean fatigue severity (CIS-fatigue) in par-
ticipants assigned to GET and/or CBT is significantly
lower at T1 compared to participants assigned to UC. A
clinically relevant difference between the intervention
arms and the UC arm of at least 6 points is expected for
the primary outcome (CIS-fatigue). Per arm, a minimum
number of 51 evaluable participants at T1 would be
needed for a t-test with a power of 0.80 and a two-sided
alpha of 0.025 (corrected to account for the two compar-
isons: GET versus UC and CBT versus UC). According
to Borm et al. [46], using analysis of covariance
(ANCOVA) instead of a t-test to analyse treatment ef-
fects on a continuous outcome measure (CIS-fatigue) in-
creases the power and reduces the needed sample size in
RCTs. This proposed ‘design factor’ for ANCOVA can
be calculated by multiplying the number of participants
needed for the t-test by 1 – p2, where p is the correlation
between the outcome measure at T0 and T1. Since no
data on the correlation of the CIS-fatigue from earlier
trials in this particular patient group were available, we
used a conservative approach by assuming a weak cor-
relation (1 – 0.102 = 0.99) and thus the number of partic-
ipants needed was not reduced. Anticipating an attrition
rate of 30%, we aim to recruit a target sample size of
219 participants at T0 (73 participants per arm).
Statistical analyses
The statistician who will perform data analyses will be
blinded for intervention allocation. To test the efficacy
of both interventions compared to UC, an ANCOVA
will be performed for each intervention with fatigue se-
verity (CIS-fatigue) at T1 as dependent measure, condi-
tion as fixed factor and CIS-fatigue screening score as
covariate [47]. Missing data is a common problem in
palliative care research and is also anticipated in our
study as a result of deteriorating health or because the
patient has died. Data will be primarily analysed on
complete case basis, i.e. only data from evaluable partici-
pants with a T1 assessment will be used. The p-level is
adjusted to 0.025 to account for the two primary ana-
lyses, i.e., GET versus UC and CBT versus UC. When
statistically significant differences between GET versus
UC and/or CBT versus UC are found, additional sensi-
tivity analysis accounting for all randomised participants
will be done to explore the impact of missing data.
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Several methods of imputation are available and the
choice will depend on the actual circumstances of miss-
ing data. We will record the causes of missing data and
careful considerations will be given to which imputation
procedure should be used.
In addition, ANCOVA will be performed for the second-
ary outcomes (fatigue, quality of life, and functional impair-
ments), with baseline score (T0) on the dependent measure
as covariate. In these exploratory analyses a p-level of 0.05
will be used. Longer-term follow-up effects at T2 and T3
will also be tested using ANCOVA, with baseline score
(T0) on the dependent measure as covariate. Again, in
these explorative analyses a p-level of 0.05 will be used. No
sensitivity analysis will be done, as the power for follow-up
analyses will be limited due to the expected significant
amount of attrition.
Mediation analysis will be conducted to explore the pos-
sible underlying mechanisms of the expected reduction in
fatigue severity (CIS-fatigue) brought on by GET and CBT
at T1. Following recommendations of Preacher and Hayes
(2008) [48], we will perform multiple mediation analysis
using bootstrapping to test the mediating effect of four po-
tential mediators (i.e., changes in physical activity, physical
fitness, self-efficacy with respect to fatigue, and catastrophis-
ing in response to fatigue). We will only perform multiple
mediation analysis when there is a significant effect of one
or both interventions compared to UC.
Ethical approval
The study protocol has been reviewed and approved by
the Research Ethics Committee of our University-
affiliated hospital (CMO Arnhem-Nijmegen, reference
no. 2012/240) and the local Ethics Committees of the
participating hospitals (Hospital Gelderse Vallei, Máxima
Medical Center, Isala Hospital, Canisius-Wilhelmina
Hospital, Hospital Pantein, Jeroen Bosch Hospital,
VieCuri Medical Center, Academic Medical Center). The
study is registered in the Dutch Trial Registry (reference
no. NTR3812, date registered: January 23, 2013).
Discussion
Fatigue is one of the most prevalent symptoms com-
promising quality of life of incurable cancer patients re-
ceiving systemic treatment with palliative intent. Graded
exercise and cognitive behavioural interventions seem
promising in reducing fatigue severity based on their ef-
fectiveness in disease-free cancer patients and patients
receiving cancer treatment with curative intent. To our
knowledge, the TIRED study will be the first RCT deter-
mining the efficacy of GET and CBT compared to UC in
reducing severe fatigue in incurable cancer patients re-
ceiving systemic treatment with palliative intent.
Recruitment of participants started in January 2013.
Thus far, identifying potential study participants via
nurses and oncologists for this palliative care RCT has
been challenging. One common barrier for recruitment
in palliative care research known from the literature is
professional gatekeeping [49]. A recent systematic review
by Kars et al. (2015) explored reasons for gatekeeping in
palliative care research, the professionals’ perception that
study participation would be too burdensome for the pa-
tients was the most reported reason [50]. Yet, we re-
cently demonstrated that 93% of incurable cancer
patients that completed a fatigue-screening question-
naire during cancer treatment with palliative intent
wanted to be informed by a researcher about available
interventional studies for fatigue [51]. Other important
reasons for gatekeeping reported by Kars et al. (2015) in-
cluded health carers’ lack of time, complicated study
procedures, or study procedures that interrupt usual
care processes [50]. These issues have also been ob-
served in our study and as a result we have simplified
our study procedures. For example, we originally aimed
to screen for the presence of severe fatigue during a
nursing consultation before the first line of systemic
treatment with palliative intent began. However, nurses
indicated that patients often raise several important
time-consuming treatment-related questions, which
hampered nurses from administering the fatigue screen-
ing. Therefore, we amended the study protocol by also
allowing patients to be screened for fatigue at consulta-
tions further on during treatment. Moreover, we initially
aimed to include a homogeneous sample of patients with
incurable breast or colorectal cancer. Then again, poor
recruitment rates during the first year, made us broaden
our inclusion criterion regarding cancer type. Finally, we
have extended our research collaboration with three
hospitals to nine hospitals in total. All study protocol
amendments have been reviewed and approved by the
Research Ethics Committee of our University-affiliated
hospital and the local Ethics Committees of the partici-
pating hospitals.
In conclusion, the TIRED study will provide informa-
tion on the efficacy of GET and CBT compared to UC in
reducing severe fatigue in incurable cancer patients, as
well as on the mediators of any observed intervention ef-
fects. Other important outcome measures will include
quality of life and functional impairments. If proven effi-
cacious, one or both interventions might be offered as
part of UC for this often overlooked and understudied
patient group.
Status of the trial
The TIRED-study started in January 2013 and patient re-
cruitment is ongoing.
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